Schumm P M, Usadel K H, Schulz F, Schumann J, Schöffling K
Dtsch Med Wochenschr. 1981 Jan 9;106(2):43-8. doi: 10.1055/s-2008-1070254.
Antithyroid medication was given to 158 patients with hyperthyroidism over a period of 3 to 60 months. After cessation of therapy patients were followed up for 18 to 90 months. Permanent euthyroidism was seen in 70 patients (44.3%) after stopping treatment, however, 88 patients (55.7%) showed recurrence of hyperthyroidism occurring 1 to 56 months after ceasing treatment. In more than 50% recurrence of hyperthyroidism was within the first 3 months and in almost 80% within the first year after end of treatment. There was no connection either between the length of thyrostatic treatment and the recurrence rate or between the length of treatment and recurrence time. Comparison of patients with and without recurrence according to various parameters prior, during and after thyrostatic treatment indicates that there is a high risk of recurrence in patients with 1) nodular and (or) large goitres, 2) marked clinical symptomatology and delayed attainment of a euthyroid state after starting conservative treatment, and 3) the symptom of sweating remaining uninfluenced by antithyroid treatment.
158例甲状腺功能亢进患者接受了3至60个月的抗甲状腺药物治疗。治疗停止后，患者接受了18至90个月的随访。停药后，70例患者（44.3%）出现永久性甲状腺功能正常，但88例患者（55.7%）在停药后1至56个月出现甲状腺功能亢进复发。超过50%的甲状腺功能亢进复发发生在停药后的前3个月内，近80%发生在治疗结束后的第一年内。甲状腺抑制治疗的时长与复发率之间，以及治疗时长与复发时间之间均无关联。根据甲状腺抑制治疗前、治疗期间和治疗后的各种参数，对复发和未复发的患者进行比较，结果表明，以下患者复发风险较高：1）有结节性和（或）大甲状腺肿的患者；2）临床症状明显且开始保守治疗后甲状腺功能正常状态的实现延迟的患者；3）抗甲状腺治疗后出汗症状仍无改善的患者。
